Ambit Biosciences, an anti-cancer drugs developer formerly known as Aventa Biosciences, has raised $15m of a planned $15.9m round of debt, rights and securities from 18 investors, according to a recent regulatory filing first seen by news provider Xconomy.
Ambit raised $49.3m in its series D round in 2007, led by venture capital firm Apposite Capital and including corporate venturing from MedImmune Ventures, which is now part of AstraZeneca; Roche Venture Fund; and Genechem. The other VCs in the D round were OrbiMed Advisors, Radius Ventures, NovaQuest, Horizon Technology Finance, Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Avalon Ventures, GIMV and Jov-CMDF.
In May 2005, Ambit made the final close of its series C round at $31m led by Roche Venture Fund, while the first two rounds raised an aggregate $20.8m in 2000.